文献速递急性肾损伤肾小球疾病

Teclistamab与CAR-T治疗复发难治多发性骨髓瘤的急性肾损伤发生率比较

Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

本回顾性研究纳入64例既往至少接受四线化疗的复发难治多发性骨髓瘤患者,比较teclistamab(34例)与CAR-T(30例)治疗后急性肾损伤(AKI)的发生率、严重程度及结局。teclistamab组AKI发生率为29%(10例),CAR-T组为13%(4例);

要点

  • teclistamab组AKI发生率29%,CAR-T组13%,但差异未达统计学显著。
  • 180天无AKI生存率teclistamab组68%,CAR-T组90%。
  • 接受teclistamab治疗者需密切监测肾功能。

核心结论

  • teclistamab治疗者AKI发生率可能高于CAR-T治疗者,但需进一步研究明确风险归因于疾病进展还是teclistamab本身。

研究设计与样本

  • 回顾性研究,纳入64例既往至少接受四线化疗的复发难治多发性骨髓瘤患者,其中30例接受CAR-T,34例接受teclistamab。

主要发现

  • 总共发生14例AKI事件(22%),teclistamab组10例(29%),CAR-T组4例(13%)。
  • 治疗开始后180天无AKI生存率:teclistamab组68%(95%CI 53%-87%),CAR-T组90%(95%CI 79%-100%)。

临床怎么用

  • 接受teclistamab治疗的复发难治多发性骨髓瘤患者应密切监测肾功能。

局限性

  • 回顾性研究设计,样本量较小(64例),AKI风险差异未达统计学显著,无法确定风险归因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B cell maturation antigen (BCMA), and chimeric antigen receptor T cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare the incidence, severity, and outcomes of AKI between patients receiving teclistamab and CAR-T therapy. METHODS: This was a retrospective study involving 64 patients with relapsed/refractory MM treated with either teclistamab or CAR-T therapy. All patients had previously received at least four lines of chemotherapy before being treated with either teclistamab or CAR-T. The primary outcome was the incidence of AKI, and secondary outcomes included AKI severity, kidney recovery rates, and mortality. Kaplan-Meier estimates for AKI-free survival were calculated, and hazard ratios (HRs) for AKI risk were determined using Cox proportional hazards models. RESULTS: Sixty-four patients met inclusion criteria for this study (30 received CAR-T and 34 received teclistamab therapy). Among these patients, 14 AKI events occurred in total (22%), with 10 events (29%) in the teclistamab group and four events (13%) in the CAR-T group. AKI-free survival estimates at 180 days after treatment initiation were 68% [95% confidence interval (CI): 53%-87%] for teclistamab patients and 90% (95% CI: 79%-100%) for CAR-T patients. While patients receiving teclistamab were found to have an increased risk of an AKI event compared to those receiving CAR-T therapy, the results were not statistically significant [HR (95% CI): 3.38 (0.93-12.31), P = .065]. CONCLUSIONS: This study suggests that patients treated with teclistamab may experience a higher incidence of AKI compared to those receiving CAR-T therapy. However, further research is required to determine whether this increased risk is attributable to disease progression or teclistamab itself. These results highlight the need for close kidney function monitoring in patients receiving teclistamab.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Charkviani M, Brochero MJV, Mohan A, et al. Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells. Nephrol Dial Transplant. 2025. PMID: 39805729. doi:10.1093/ndt/gfaf004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。